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This study investigates the eﬀects and possible mechanism of an agonist of PPARα, Wy14643, on primary hepatocytes subjected to
H/R injury in rats. H/R induced a signiﬁcant increase ALT, AST, MDA in the culture medium and ROS in the hepatocytes. These
eﬀects were reversed by pretreatment with Wy14643 in the dose-dependent manner. The activity of SOD and the level of GSH
in the hepatocytes were decreased after H/R, which were increased by Wy14643 pretreatment. Moreover, the mRNA expressions
of PPARα signiﬁcantly increased in H/R+Wy14643 groups when compared with that in H/R group. A PPARα agonist, Wy14643,
exerts signiﬁcant protective eﬀect against H/Rinjury in primaryhepatocytes via PPARα activation and attenuating oxidative stress.
1.Introduction
Ischemia/reperfusion (I/R) injury is a serious complication
precipitated during short-term expansion of the invading
parasitic pathogens, such as by Entamoeba histolytica as the
infections lead to local tissue damage and hypoxia [1]. The
condition has also been reported to occur in certain intra-
cellular bacterial infections, for example, Chlamydia species.
Mechanisms of I/R injury involve complex and multiple
pathways, including the direct ischemic cellular damage as
well as the cell injury due to the activation of inﬂam-
matory response after reperfusion [2]. A hepatic, in vitro
hypoxia/reoxygenation (H/R) model can be use to study the
pathophysiology of this injury [3]. Previous study showed
that the generation of reactive oxygen species (ROS) is likely
to be an important factor in H/R-induced cell damage. Thus,
ROS are generated immediately after H/R and activate
proapoptotic/inﬂammatory signalling in the cell or directly
damage cell organelles. These include direct oxidation of cel-
lular components and lipids (lipid peroxidation), activation
of inﬂammatory gene transcription, and possible activation
of the innate immune response [2, 3]. Administration of an-
tioxidantssuchasglutathionecouldaﬀordprotectionagainst
I/R injury [4, 5]. Oxygen deprivation (hypoxia) during is-
chemia and subsequent reoxygenation upon reperfusion
are thought to be the major factors contributing to ROS
production and the subsequent cellular damage [6]. Hypoxia
increases mitochondrial reactive oxygen species (ROS) gen-
eration at Complex III, and the predominant source of ROS
by oxygen limitation originates from mitochondria [7]. Per-
oxisome proliferator-activated receptors (PPARs) are mem-
bers of the nuclear receptor related to retinoid, steroid,
and thyroid hormone receptors. Peroxisome proliferator-
activated receptor-α (PPARα) is one of the three subtypes
of the nuclear receptor PPAR family [8]. The structure of
PPARα consists of an aminoterminal region that allows for
ligand-independent activation and constitutive activity on
the receptor and is negatively regulated by phosphorylation
and the carboxyl-terminal ligand binding domain. PPARα
has a wide range of eﬀects on metabolism, cellular prolif-
eration and the immune response [9]. Besides its metabolic
regulating eﬀects, PPARα also exerts anti-inﬂammatory and
antioxidant eﬀects in diﬀerent organs. As is well known that
PPARαhaveanti-inﬂammatoryproperties[10],weproposed
that it may have a similar eﬀects on hepatic I/R injury.
Previous studies suggest that PPARα agonists protect many2 PPAR Research
organs against I/R injury such as heart [11], kidney [12],
and brain [13]. PPARα agonists can inhibit the expression
of oxidative stress genes via a mechanism termed ligand-
dependent repression by PPARα. It has been demonstrated
that the anti-inﬂammatory eﬀect of PPARα ligands is also
dependent on the inhibition of functional NF-κBa c t i v a t i o n
and AP-1 activation [14]. Furthermore, PPARα stimulation
byWy14643inducesexpressionandactivationofantioxidant
enzymes such as superoxide dismutase (SOD), catalase, and
glutathione (GSH), which protects hepatocytes against hep-
atic I/R injury mice model in vivo [15]. These beneﬁcial
eﬀectsof Wy14643 are possibly associated withenhancement
of anti-oxidant and inhibition of inﬂammation response.
Razeghi et al. have found a downregulation in expression of
PPARα in a rat model of hypoxia [16]. However, there is no
report about the eﬀect of H/R on expression of hepatocytes
PPARα-mRNA in vitro. In the present study, we determined
whether PPARα activation by the selective agonist Wy14643
had a protective role in H/R injury of hepatocytes in vitro.
2.MaterialsandMethods
2.1. Animals. Male Sprague-Dawley rats (weighing 220–
280g) were used in these experiments. Temperature and
relative humidity were kept at (22 ± 2)◦Ca n d( 5 0± 5)%,
respectively. All rats were obtained from the Center of Exper-
imental Animals in Anhui Medical University. This project
was approved by the Committee for Research and Animal
Ethics of the Anhui Medical University. They were allowed
free access to a commercial standard chow and water ad lib-
itum before the experimental procedure began. All rats were
acclimatized to our animal facility for at least 1 week before
experiment to avoid stressful stimuli.
2.2. Hepatocyte Isolation and Culture. Rat hepatocytes were
isolated and cultured as previously described [17]. Male
Sprague-Dawley rat livers were minced after perfusion with
0.5g/L collagenase IV (Sigma, USA) through the portal vein.
Hepatocytes were separated from nonparenchymal cells by
centrifugation at 50g for 4min at 4◦C. The viability of the
collected hepatocytes exceeded 90%, as determined by the
trypan blue exclusion test. Hepatocytes were resuspended
in William’s E medium (Gibco, USA) containing 100mL/L
fetal calf serum, 27×10
−6 mol/L NaHCO3, 100×10
−9 mol/L
insulin, and 10×10
−9 mol/L dexamethasone at pH 7.4. Hep-
atocytes were then plated on type I collagen—coated 24—
multiwell plates and incubated overnight in an atmosphere
of95%airand5%CO2 at37◦C.Cellswerestudiedaccording
to the experimental protocols.
2.3. Hypoxia/Reoxygenation Treatments and Groups. H/R
injury in vitro was performed as previously described [18].
Hepatocytes were isolated and maintained overnight at 37◦C
in a humidiﬁed incubator containing 95% air and 5% CO2
(referred to as normoxic conditions). The next day, hypoxic
conditions were attained by exposure to 95% N2 and 5%
CO2 gas mixture in a humidiﬁed incubator for 4h. Hypoxic
exposure was conﬁrmed in each experiment by measuring
the ambient PO2 of the gas above the monolayers. Reoxy-
genation of hypoxic cultures was achieved with normoxia
conditions for another 10h, whose ambient values should
return to pre-hypoxic levels within 5min. Six groups of
culture hepatocytes (6 wells each) were separated as follows.
(1) The control group was exposed to normoxic medium for
14h. (2) The H/R injury group was exposed to hypoxic (4h)
andthenreoxygenation(10h)conditionsasdescribedabove.
(3) Model H/R hepatocytes treated with diﬀerent doses of
Wy14643 (10×10
−6,3 0×10
−6, and 100×10
−6 mol/L, resp.)
(Pirinixic acid, CAS 50892-23-4, Cayman Chemical, USA).
Diﬀerent concentrations of Wy14643 were added to the
culture medium 60min before H/R course [15]. Wy14643
were prepared in 10%(v/v) DMSO (dimethyl sulfoxide) and
90%(v/v) William’s E medium. The ﬁnal DMSO concentra-
tion in cell cultures was 0.1% (this concentration aﬀected
neither cell viability nor hepatocytes damage). (4) DMSO
group hepatocytes were pretreated for 60min with 0.1%
DMSO before H/R.
2.4. Mitochondria Isolation. The cell medium was collected,
c e n t r i f u g e da t4 5 0gt or e m o v ec e l ld e b r i s .T h eh e p a t o c y t e s
mitochondrial fraction was prepared according to the meth-
od reported by Johnson and Lardy. The homogenate was
centrifugedat600gfor10min,andthesupernatantwascen-
trifuged for 5min at 15,000g to obtain the mitochondrial
pellet which was washed with a medium and centrifuged for
5min at 15,000g.
2.5. Measurement of Intracellular ROS Generation. 2,7-Di-
chloroﬂuorescein diacetate (DCFH-DA) was used as indica-
tiorofintracellularformationofROSasdescribedpreviously
[19]. DCFH-DA is cell-permeant probe that enters the cell
followed by cleavage of the diacetate molecules by cellular
esterases. The probe becomes ﬂuorescent when it is oxidized
in cells by ROS. In brief, hepatocytes were plated onto 24-
well plates at a density of 60,000cells/well. 24h after plating,
cellswerewashedtwicewithPBSandsubsequentlyincubated
in PBS+ containing 10μM DCHFH-DA (Invitrogen, Calif,
USA) for 45min at dark. Subsequently, cells were rinsed
with PBS, and 500μL of fresh Earle’s salt solution was added
to each well. Fluorescence was measured using prewarmed
SpectraMax (Molecular Devices, Calif, USA) spectroﬂuo-
rometer, with excitation wavelengths of 485/535nm for
20min. The slope of the linear part of the graph was used
to calculate the rate of increases in ﬂuorescence. As a positive
control,H2O2 wasaddedjustbeforeplacingtheplateintothe
p l a t er e a d e r .T h ei n c r e a s ei nﬂ u o r e s c e n c eb yR O Sp r o d u c t i o n
was expressed as % of control.
2.6. Detection of Aminotransferase (ALT), Aspartate Amino-
transferase (AST), and Malondialdehyde (MDA) Level in Cul-
tureMedium. TheLipidperoxidationinculturedhepatocyte
was determined by detecting the level of MDA, which is the
end product of lipid peroxidation; in the liver mitochondria
was determined by measuring the level of the thiobar-
bituric acid-reactive substances spectrophotometrically at
532nm according to the method reported by Buege andPPAR Research 3
Aust. ALT and AST, markers of hepatocellular injury, were
measured using commercial available kit. These assay kits
were purchased from the Jiancheng Bioengineering Institute
(Jiancheng, China) [20].
2.7. Measurement of Glutathione (GSH) Levels and Activity of
SupeoxideDismutase(SOD)intheHepatocytes. GSHcontent
was measured by the Owens and Belcher method, which
was determined using the following procedure. The isolated
mitochondria were suspended in a buﬀer (pH 7.5) contain-
ing 0.1mol/L sodium phosphate and 5mmol/L EDTA. After
precipitating with 15%(w/v) sulfosalicylic acid containing
5mmol/L EDTA, the total glutathione level was measured
spectrophotometricallyatawavelengthof412nmusingyeast
glutathione reductase and 5,50-dithio-bis(2-nitrobenzoic
acid), as described by Tietze. SOD activity was measured
through the inhibition of nitroblue tetrazolium (NBT) re-
duction by O2 generated by the xanthine oxidase system. The
content of GSH and activity of SOD were measured using
commercial kits (Jiancheng, China) [21].
2.8. Ultrastructure Assessment of Rat Hepatocytes. Hepato-
cytes ﬁxed in 10g/L Glutaral, dehydrated, dried and surface
gilded according to standard procedures. Electron micro-
scope was used to assess the degree of hepatic damage (JEM-
1010, JEOL, Japan).
2.9. Measurement of PPARα mRNA Levels by Real-Time
Polymerase Chain Reaction (Real Time PCR). Total RNA was
e x t r a c t e df r o mc u l t u r e dh e p a t o c y t e sa sr e c e n t l yd e s c r i b e d .
TotalRNAwasextractedusingtheTrizolreagent(Invitrogen,
USA), the value A at 260/280nm was detected, and the
concentration of RNA was calculated. cDNA was synthesized
according to the manufacturer’s instruction for the reverse
transcription kit (Promega, USA), then semiquantitative
real-time polymerase chain reaction analysis using SYBR
Green PCR Master Mix (Invitrogen, USA). The cDNAs
were quantiﬁed with an ABI StepOne sequence detection
system (Applied Biosystems, Calif, USA). Primers were
synthesized by Sangon (China). The rat, speciﬁc primer
(sense and antisense primers) for PPARα was sense: 3 -
GTGGCTGCTATAATTTGCTGTG-5 , antisense: 5 -GAA-
GGTGTCATCTGGATGGGT-3 .T h ep r i m e rβ-action was
sense: 5 -TGGAATCCTGTGGCATTCCATCCATGAAAC-
3 , antisense: 5 -AGGCTATCCCAGGCTTTGC-3 .R e a l -
time PCR was performed in a 25μL of reaction containing
12.5μL of 2X SYBR Green Supermix, 200nM primers and
cDNA. The cycles for PCR were as follows: 95◦Cf o r2 0 s ,
54◦C for 7min, 40 cycles of 95◦C for 20s, 54◦C for 30s, and
72◦C for 30s. The fold changes in gene expression of PPARα
was calculated using the comparative Ct (cross-threshold)
method.BrieﬂytheCt ofthehousekeepinggeneβ-actionwas
subtracted from the Ct of PPARα to get ΔCt.T h eΔCt value
of control sample was the subtracted ΔCt of the rest of the
treatments to get the ΔΔCt value. Fold diﬀerences compared
to control sample are obtained by calculating 2−ΔΔCt for each
treatment group.
2.10. Statistical Analyses. All data were expressed as mean ±
SD. The statistical signiﬁcance of diﬀerences between groups
wasanalyzedusingtheone-wayanalysisofvariance(ANOVA)
and methods of LSD with the SPSS11.5 for windows XP
statistical software package. The P values less than 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Pretreatment with the PPARα Agonist Wy14643 Decreases
Hepatocytes Damage Induced by H/R Injury. ALT and AST
levels in the medium of hepatocytes cultured under normal
condition and H/R stress were shown in Figures 1(a) and
1(b), respectively. ALT and AST level increased after H/R
(ALT, P = 0.006; AST, P = 0.0032). The increase in the
medium ALT as well as AST activity induced by hepatic
H/R was signiﬁcantly attenuated by pretreatment Wy14643
(100×10
−6,3 0×10
−6,1 0×10
−6 mol/L) in a dose-dependent
manner. (ALT, P = 0.004; P = 0.095; P = 0.041. AST,
P = 0.001; P = 0.0062; P = 0.0071.) DMSO group was not
considered statistically when compared with H/R group
(P = 0.08) the results demonstrated Wy14643 has the dose-
dependent protective eﬀects on hepatic injury.
3.2. Pretreatment with the PPARα Agonist Wy14643 Increases
Antioxidant Enzymes Induced by H/R Injury. The MDA level
increased after H/R and maintained at a considerably high
concentration during the period of cultivation (P = 0.008).
Wy14643-pretreated group (100 × 10
−6,3 0× 10
−6,1 0×
10
−6 mol/L) exhibited a decrease in the content of MDA
compared with H/R group (P = 0.0025; P = 0.0094;
P = 0.056) (Figure 1(c)) .S O Da n dG S Hw e r ep r e s e n t e d
in Figure 2(a) and Figure 2(b). In H/R group, both these
enzymes activities were signiﬁcantly lower when compared
with control group (SOD, P = 0.0003; GSH, P = 0.0005).
But in the Wy14643-pretreated group (100×10
−6,3 0×10
−6,
10 × 10
−6 mol/L), the antioxidant activities were markedly
higherwhencomparedwiththeH/Rgroup(SOD,P = 0.002;
P = 0.059; P = 0.076. GSH, P = 0.0017; P = 0.0075;
P = 0.0098). DMSO group was not considered statistically
when compared with H/R group (P = 0.085).
3.3. Pretreatment with the PPARα Agonist Wy14643 Decreases
ROS Induced by H/R Injury. ROS levels in the hepatocytes
cultured under normal condition and H/R stress were shown
Figure 3. ROS level increased after H/R (ROS, P = 0.0032),
The increase in the hepatocytes induced by hepatic H/R
was signiﬁcantly attenuated by pretreatment of Wy14643
(100×10
−6,3 0×10
−6,1 0×10
−6 mol/L) in a dose dependent
manner. (P = 0.0025; P = 0.0070; P = 0.0090). DMSO
group was not considered statistically when compared with
H/R group (P = 0.08); the results demonstrated Wy14643
has the dose-dependent decrease ROS on hepatic injury.
3.4. PPARα Agonist Wy14643 Upregulates Hypoxia-/Reoxy-
genation-Induced PPARα-mRNA Expression in Hepatocytes.
PPARα-mRNA expression was assessed in the absence and
presence of Wy14643 during inducing hepatocytes by H/R.4 PPAR Research
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Figure 1: (a) ALT in diﬀerent groups (Mean ± SD, n = 6). After 4h of hepatocellular hypoxia and 10h of reoxygenation. The levels of ALT
in hepatocytes medium were determined. cP < 0.01 versus control group; eP < 0.05, fP < 0.01 versus H/R group. (b) AST in diﬀerent
groups (Mean ± SD, n = 6). After 4h of hepatocellular hypoxia and 10h of reoxygenation. The levels of AST in hepatocytes medium were
determined. cP < 0.01 versus control group; fP < 0.01 versus H/R group. (c) MDA in diﬀerent groups (Mean ± SD, n = 6). After 4h of
hepatocellular hypoxia and 10h of reoxygenation. The levels of MDA in hepatocytes determined. cP < 0.01 versus control group; fP < 0.01
versus H/R group.
Quantitative analysis showed that the mRNA expressions of
PPARα in the H/R group was signiﬁcantly decreased when
compared with the control group (P = 0.005). However,
when comparing the Wy14643 group (100×10
−6,3 0×10
−6,
10 × 10
−6 mol/L) with the H/R group, mRNA expressions of
PPARα were increased after the addition of Wy14643 (P =
0.0018; P = 0.0073; P = 0.0098) (Figure 4). DMSO group
was not considered statistically when compared with H/R
group (P = 0.065).
3.5. Ultrastructure Alterations of Hepatocytes. The ultra-
s t r u c t u r eo fh e p a t o c y t e sw a sn o r m a li nt h ec o n t r o lg r o u p
(Figure 5(a)). Compared with the control group, H/R group
was markedly damaged characterized by mitochondrial
crista destruction markedly decreased and nucleus structure
destruction (Figure 5(b)). In Figure 5(c), Wy14643 group
(100 × 10
−6 mol/L), almost normal appearance of mito-
chondrion and nucleus structure. In Figure 5(d), Wy14643
group (30×10
−6 mol/L), Mitochondrion swelled mildly and
normal nucleus structure. In Figure 5(e), Wy14643 group
(10 × 10
−6 mol/L), Mitochondrion swelled moderatedly,
withmitochondrial cristainterruption andnucleusstructure
destruction. In Figure 5(f) (DMSO group), mitochondrion
swellen signiﬁcantly and nucleus structure destruction.
4. Discussion
This study provides compelling evidence that the selective
PPARα agonist Wy14643 protects the hepatocytes from
transient H/R injury. An increase in the cell medium’s ALTPPAR Research 5
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Figure 2: (a) SOD in diﬀerent groups (Mean ± SD, n = 6). After 4h of hepatocellular hypoxia and 10h of reoxygenation. The levels of SOD
in hepatocytes determined. cP < 0.01 versus control group; fP < 0.01 versus H/R group. (b) GSH in diﬀerent groups (Mean ± SD, n = 6).
After 4h of hepatocellular hypoxia and 10h of reoxygenation. The content of GSH in hepatocytes mitochondria fractions was determined.
cP < 0.01 versus control group; fP < 0.01 versus H/R group.
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Figure 3: The content of ROS in diﬀerent groups was determined
by DCFH-DA (Mean ± SD, n = 6). After 4h of hepatocellular
hypoxia and 10h of reoxygenation. cP < 0.01 versus control group;
fP < 0.01 versus H/R group.
and AST levels has been usually used as an eﬀective indicator
of impaired hepatocytes with H/R. The protective eﬀect of
Wy14643 demonstrated herein by reducing ALT and AST
levels is associated with an inhibition of oxidative stress
and upregulation of hepatocytes PPARα-mRNA expression.
Previous studies provided evidence that Wy14643 protected
the rat liver from hepatic I/R injury [10]. In our study, we
found that pretreatment of Wy14643 resulted in a marked
reduction of ALT and AST levels with dose-dependent man-
ner in the cell medium compared with the control group, as
well as we demonstrated a signiﬁcant down regulation in
PPARα-mRNA after H/R, and this downregulation was sig-
nificantly attenuated by Wy14643.
The precise sequence of events leading to hepatic I/R is
still a matter of debate. However, two major culprits have
been identiﬁed including uncontrolled oxidative stress and
unfettered inﬂammation, whose eﬀects culminate in the ne-
crotic cell death of hepatocytes, the hallmark of severe he-
patic I/R [22]. Therapies aimed at curbing inﬂammation and
blocking oxidative necrosis of hepatocytes in the setting of
hepatic I/R have been heavily explored. The precise sequence
of events leading to hepatic I/R has not been completely
elucidated. As is well known H/R has been shown to
stimulate a burst of ROS of mitochondrial and extra mito-
chondrial origin; as reported, ROS was generated by cytosol
and mitochondria, in diﬀerent cell types cultured under 1.5–
5%O2 [23, 24]. Although hypoxia stimulates ROS genera-
tion and the contribution of mitochondria to this process
may vary depending on whether reoxygenation follows the
hypoxic phase, it has been reported that Wy14643 uncouples
mitochondrial oxidative phosphorylation in isolated hepatic
mitochondria [25]. MDA is the end product of lipid per-
oxidation considered as a sensitive index to assess lipid
peroxidation [26]. SOD, an oxygen radical scavenger which
converts superoxide anion radicals present in the upper
stream of reactive oxygen metabolism cascade and protects
cells against damage. The hepatic MDA levels signiﬁcantly
increased, indicating the presence of enhanced lipid perox-
idation due to H/R injury [27], whereas the level of SOD
declined, demonstrating the depletion of antioxidant pool
in hepatocytes H/R. In this study we showed that Wy14643
signiﬁcantly decreased MDA levels in the hepatocytes when
compared with the H/R group. In addition, high levels
of SOD were observed in the Wy14643-pretreated groups.
According to these ﬁndings, Wy14643 has protective eﬀects
against the oxidative stress induced hepatocytes injury. This
ﬁnding is in agreement with other reports showing that
Wy14643 enhances expression of antioxidant enzymes such6 PPAR Research
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Figure 4: After 4h of hepatocellular hypoxia and 10h of reoxy-
genation. Eﬀe c to fh y p o x i aa n dr e o x y g e n a t i o no nP P A R α-mRNA
expression in hepatocytes. (Mean ± SD, n = 6) cP < 0.01 versus
control group; eP < 0.05, fP < 0.01 versus H/R group. (C: control
group; H/R: hypoxia/reoxygenation group; I: Wy14643 group 100
× 10−6 mol/L; II: Wy14643 group 30 × 10−6 mol/L; III: Wy14643
group 10 × 10−6 mol/L; D: DMSO group).
as SOD and catalase in the rat liver [28]. Our data suggests
that the mechanism underlying the protective action of
Wy14643 against hepatocellular H/R is the direct ROS
scavenging eﬀect.
GSHisamajorcellularantioxidantwhichisfoundmain-
ly in cytosol where it is synthesized from its constituent ami-
no acids and in mitochondria where it plays a key protective
role against oxidant-induced cell death [29]. Because of its
antioxidant function, hypoxia would be expected to reduce
intracellular GSH stores. The present study examined for the
ﬁrst time the impact of mitochondria GSH depletion on the
survival of hepatocytes which were pretreated by Wy14643
during exposure to hypoxia. Previous studies reported the
decrease of hepatocellular GSH stores by hypoxia. This study
addressed the role of GSH, particularly in mitochondria,
on the susceptibility of hepatocytes to hypoxia-induced
oxidativestress.ConsistentwiththeburstofROSgeneration,
it has been shown that hypoxia depletes GSH stores [30, 31].
In agreement with these ﬁndings we showed GSH depletion
in both cytosol and mitochondrial compartments compared
with H/R. Here, we found that Wy14643 increased the con-
tent of GSH in the hepatocytes which were induced by H/R.
Our result showed that Wy14643 signiﬁcantly increased the
production of GSH compared with the H/R group.
In the present study, we found that H/R stress lead to
decreasesofPPARα-mRNAinhepatocytes.Avarietyofstim-
uli,includinghypobarichypoxia,arealsocapableofinducing
a switch in substrate use associated with downregulation
of PPARα-regulated genes [32, 33]. Wy14643 attenuates the
increase in PARP (poly-ADP-ribose polymerase) activity
caused by splanchnic artery occlusion (SAO) shock, ROS
produce strand breaks in DNA, which trigger energy-con-
suming DNA repair mechanism and activate the nuclear
enzyme PARP. PARP plays an important role in ischemia/
reperfusion injury. PARP activation results in the depletion
of its substrate NAD+ and also in a reduction in the rate of
glycolysis. As NAD+ functions as a cofactor in glycolysis and
the tricarboxylic acid cycle, NAD+ depletion leads to a rapid
fall in intracellular ATP rapidly followed by cellular dysfunc-
tion and death—the PARP Suicide Hypothesis. Huss et al.
[33] found that hypoxia deactivates PPARα by reducing the
availability of its obligate partner RXR (retinoid X receptor).
Mitochondrial oxidative phosphorylation is inhibited, and
ATP generation is reduced, which aggravates hepatocellular
anoxic injury. Hence, PPARα may improve the energy sup-
plement of hepatocytes meanwhile enhancing the anti-ische-
miaabilityofhepatocytes.Previousdatashowedaratcardiac
model of hypoxia and have found a downregulation in its
expression of PPARα [34]. These results show, similar to our
study, that the expression of PPARα-mRNA in hepatocytes
which were exposed to H/R was reduction. After pretreat-
ment of Wy14643, the expression of PPARα-mRNA in-
creased;meanwhile,thedamageofhepatocyteswasrelieving.
Thus, it is conceivable; the expression of PPARα during in-
ﬂammation and hypoxia may serve as a counter regulator of
ROS production.
In summary, PPARα agonist Wy14643 decreased the
injury degree with the hepatocytes H/R injury model, which
is associated with modulating the expression of PPARα.
Moreover, Wy14643 also protected the hepatocytes against
oxidative stress. These ﬁndings are particularly interesting
because they demonstrate that a regulatory factor PPARα
expressed in liver parenchymal cells, but not in Kupﬀer cells,
may have signiﬁcant impact on the hepatic inﬂammatory
response.Fromaclinicalstandpoint,mostofthenewknowl-
edge that we have gathered on the multiple “hepatoprotec-
tive”functionsofPPARαincludingprotectionfromoxidative
necrosis is both conceptually important and directly relevant
to clinical problems associated with liver transplantation
and liver disease. However, before the clinical therapeutic
application of this agent, further investigations should be
performed. The eﬀects of Wy14643 on prolonged H/R injury
or the eﬀects on the chronic phase should be studied.
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